Galderma Boosts Annual Targets as Global Skincare Sales Hit $3.13 Billion
The Swiss dermatology firm reported a 24.6% surge in first-half sales, prompting an upward revision of its full-year growth outlook. Strength in injectable aesthetics and international markets drove the record performance.
Financial Performance and Market Expansion
Galderma reported net sales of US$3.13 billion for the first half of the year, representing a 24.6% increase. This growth reflects sustained demand across the company's dermatology and injectable aesthetics lines. Based on these figures, the Swiss skincare specialist now expects full-year sales growth between 19% and 21%, a shift from its earlier projection of 17% to 20%.
Strategic Infrastructure and Regulatory Updates
To support its growing volume, Galderma is executing a broad manufacturing expansion. Current initiatives include:
- Boosting production capacity at existing facilities in the United States.
- Evaluating potential new manufacturing sites within Asian markets.
- Addressing outstanding observations from the U.S. Food and Drug Administration regarding Relfydess, the company's botulinum toxin candidate.
Evaluating Risk and Resilience
Despite the positive momentum, management noted a softening in consumer sentiment in specific regions. Internal analysis suggests that while geopolitical tensions and tariff uncertainties persist, these pressures are currently manageable within the existing business model. Double-digit gains in both U.S. and international territories indicate that the premium skincare sector maintains stability even as broader macroeconomic conditions fluctuate. The firm remains focused on its innovation pipeline to secure long-term market share in the competitive aesthetics space.
Source: Global Cosmetics News
